用T细胞重定向双特异性抗体对急性淋巴细胞白血病和淋巴瘤进行免疫治疗 - Suppr

Suppr

超能文献

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.

作者信息

Lussana Federico, Gritti Giuseppe, Rambaldi Alessandro

机构信息

Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

Department of Oncology-Hematology, University of Milan, Milan, Italy.

出版信息

J Clin Oncol. 2021 Feb 10;39(5):444-455. doi: 10.1200/JCO.20.01564. Epub 2021 Jan 12.

DOI:10.1200/JCO.20.01564

PMID:33434063

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8078487/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/afe1/8078487/4e6259be19bc/jco-39-444-g001.jpg

相似文献

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell-Redirected Bispecific Antibodies.用T细胞重定向双特异性抗体对急性淋巴细胞白血病和淋巴瘤进行免疫治疗

J Clin Oncol. 2021 Feb 10;39(5):444-455. doi: 10.1200/JCO.20.01564. Epub 2021 Jan 12.

[Chinese consensus for the bispecific T cell engager in the treatment of acute lymphoblastic leukemia (2024)].《双特异性T细胞衔接器治疗急性淋巴细胞白血病中国专家共识（2024年版）》

Zhonghua Xue Ye Xue Za Zhi. 2024 Jul 14;45(7):629-636. doi: 10.3760/cma.j.cn121090-20240528-00194.

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.双特异性、T 细胞募集抗体在 B 细胞恶性肿瘤中的应用。

Front Immunol. 2020 May 7;11:762. doi: 10.3389/fimmu.2020.00762. eCollection 2020.

Bispecific antibodies in acute lymphoblastic leukemia therapy.双特异性抗体在急性淋巴细胞白血病治疗中的应用。

Expert Rev Hematol. 2020 Nov;13(11):1211-1233. doi: 10.1080/17474086.2020.1831380. Epub 2020 Nov 4.

[Bispecific antibodies in onco-hematology: Applications and perspectives].[双特异性抗体在肿瘤血液学中的应用与前景]

Bull Cancer. 2021 Oct;108(10S):S195-S204. doi: 10.1016/j.bulcan.2021.10.002.

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.引导 T 细胞清除 B 细胞急性淋巴细胞白血病：双特异性 T 细胞衔接器和嵌合抗原受体。

Leukemia. 2017 Apr;31(4):777-787. doi: 10.1038/leu.2016.391. Epub 2016 Dec 28.

Pediatric Acute Lymphoblastic Leukemia.小儿急性淋巴细胞白血病

Oncology (Williston Park). 2019 Aug 23;33(8):683732.

Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.blinatumomab，一种双特异性 B 细胞和 T 细胞衔接抗体，用于治疗 B 细胞恶性肿瘤。

Hum Vaccin Immunother. 2019;15(3):594-602. doi: 10.1080/21645515.2018.1540828. Epub 2018 Nov 20.

Immunotherapy in pediatric B-cell acute lymphoblastic leukemia.儿童 B 细胞急性淋巴细胞白血病的免疫治疗。

Hum Immunol. 2019 Jun;80(6):400-408. doi: 10.1016/j.humimm.2019.01.011. Epub 2019 Feb 1.

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?血液系统恶性肿瘤中的双特异性抗体：何时、应用于何人以及如何才能最佳使用？

Curr Oncol Rep. 2019 Feb 4;21(2):17. doi: 10.1007/s11912-019-0759-5.

引用本文的文献

CXCR4-targeted theranostics in acute leukemia: disrupting leukemic cell-microenvironment interactions with pentixafor and pentixather.急性白血病中靶向CXCR4的诊疗一体化：利用喷替沙氟和喷替沙肽破坏白血病细胞与微环境的相互作用

Med Oncol. 2025 Aug 4;42(9):402. doi: 10.1007/s12032-025-02924-w.

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy.肿瘤免疫治疗学会愿景：有机会更深入了解抗肿瘤活性、毒性和耐药性机制，以优化癌症免疫治疗。

J Immunother Cancer. 2025 Jun 25;13(6):e011929. doi: 10.1136/jitc-2025-011929.

Incorporating Immunotherapy with Radiotherapy for Lymphomas.淋巴瘤的免疫疗法与放射疗法联合应用

Lymphatics. 2023 Dec;1(3):273-286. doi: 10.3390/lymphatics1030018. Epub 2023 Dec 7.

Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms.开发一种针对T细胞受体TRBV5-1区段的重组人IgG1单克隆抗体，用于治疗成熟T细胞肿瘤。

Front Immunol. 2024 Dec 17;15:1520103. doi: 10.3389/fimmu.2024.1520103. eCollection 2024.

Bispecific antibodies in follicular lymphoma.滤泡性淋巴瘤中的双特异性抗体。

Haematologica. 2025 Jul 1;110(7):1472-1482. doi: 10.3324/haematol.2024.285245. Epub 2024 Oct 31.

J Cell Mol Med. 2024 Jul;28(13):e18470. doi: 10.1111/jcmm.18470.

Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.裸抗体和抗体药物偶联物：儿童急性淋巴细胞白血病的靶向治疗。

Haematologica. 2024 Jun 1;109(6):1700-1712. doi: 10.3324/haematol.2023.283815.

Predictive model for the risk of cytokine release syndrome with glofitamab treatment for diffuse large B-cell lymphoma.用于评估戈利妥单抗治疗弥漫性大B细胞淋巴瘤时细胞因子释放综合征风险的预测模型。

Blood Adv. 2024 Jul 23;8(14):3615-3618. doi: 10.1182/bloodadvances.2023011089.

Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL.在 B 细胞惰性 NHL 或 CLL 患者中输注自体、Blinatumomab 扩增 T 细胞（BET）后迅速免疫重建。

Blood Cancer J. 2024 Apr 26;14(1):73. doi: 10.1038/s41408-024-01057-z.

A bibliometric and knowledge-map analysis of bispecific antibodies in cancer immunotherapy from 2000 to 2023.2000年至2023年癌症免疫治疗中双特异性抗体的文献计量学与知识图谱分析

Heliyon. 2024 Jan 17;10(2):e23929. doi: 10.1016/j.heliyon.2023.e23929. eCollection 2024 Jan 30.

本文引用的文献

Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.经基因编辑的 CAR T 细胞睡眠美人实现抗白血病活性而无严重毒性。

J Clin Invest. 2020 Nov 2;130(11):6021-6033. doi: 10.1172/JCI138473.

Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤接受博纳吐单抗治疗后完全缓解的持久性

Leuk Lymphoma. 2020 Nov;61(11):2767-2770. doi: 10.1080/10428194.2020.1783442. Epub 2020 Jul 7.

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.开放标签、2 期研究：blinatumomab 二线治疗复发/难治侵袭性 B 细胞非霍奇金淋巴瘤。

Leuk Lymphoma. 2020 Sep;61(9):2103-2112. doi: 10.1080/10428194.2020.1759055. Epub 2020 Jun 16.

Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies.双特异性、T 细胞募集抗体在 B 细胞恶性肿瘤中的应用。

Front Immunol. 2020 May 7;11:762. doi: 10.3389/fimmu.2020.00762. eCollection 2020.

Controversies in the Treatment of Follicular Lymphoma.滤泡性淋巴瘤治疗中的争议

Hemasphere. 2020 Jan 10;4(1):e317. doi: 10.1097/HS9.0000000000000317. eCollection 2020 Feb.

Treatment of Aggressive B Cell Lymphomas: Updates in 2019.侵袭性 B 细胞淋巴瘤的治疗：2019 年的更新。

Curr Hematol Malig Rep. 2020 Jun;15(3):225-234. doi: 10.1007/s11899-020-00581-6.

Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia.Blinatumomab 巩固和维持治疗成人复发/难治性 B 前体急性淋巴细胞白血病。

Blood Adv. 2020 Apr 14;4(7):1518-1525. doi: 10.1182/bloodadvances.2019000874.

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.在复发/难治性Ph阴性B细胞前体急性淋巴细胞白血病儿童患者中，博纳吐单抗与历史标准疗法的对比研究

Leukemia. 2020 Sep;34(9):2473-2478. doi: 10.1038/s41375-020-0770-8. Epub 2020 Feb 24.

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.复发/难治性急性淋巴细胞白血病患者使用博纳吐单抗挽救治疗后异基因造血细胞移植的结局

Biol Blood Marrow Transplant. 2020 Jun;26(6):1084-1090. doi: 10.1016/j.bbmt.2020.01.029. Epub 2020 Feb 5.

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.DuoBody-CD3xCD20 在临床前模型中可诱导强烈的 T 细胞介导的恶性 B 细胞杀伤作用，并为皮下给药提供了机会。

EBioMedicine. 2020 Feb;52:102625. doi: 10.1016/j.ebiom.2019.102625. Epub 2020 Jan 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验